CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia ; volume:22 ; number:1 ; day:13 ; month:3 ; year:2024 ; pages:1-15 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (13.3.2024), 1-15, 12.2024
- Creator
-
Yang, Na
Zhang, Caili
Zhang, Yingchun
Fan, Yuting
Zhang, Jing
Lin, Xiaojin
Guo, Ting
Gu, Yangzuo
Wu, Jieheng
Gao, Jianmei
Zhao, Xing
He, Zhixu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-04990-6
- URN
-
urn:nbn:de:101:1-2405152104182.675630053391
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yang, Na
- Zhang, Caili
- Zhang, Yingchun
- Fan, Yuting
- Zhang, Jing
- Lin, Xiaojin
- Guo, Ting
- Gu, Yangzuo
- Wu, Jieheng
- Gao, Jianmei
- Zhao, Xing
- He, Zhixu
- SpringerLink (Online service)
Other Objects (12)
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
CD20 and CD19 targeted vectors induce minimal activation of resting B lymphocytes
CD19 and CD20 Targeted Vectors Induce Minimal Activation of Resting B Lymphocytes
High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Chimeric Antimicrobial Peptides Exhibit Multiple Modes of Action